3M settles ‘forever chemical’ personal injury claims for $7B
The manufacturing giant 3M has faced many lawsuits over forever chemicals in their military grade firefighting foam. Forever chemicals are perfluoroalkyl and poly fluoroalkyl substances (PFAS) that stay in the environment for hundreds of thousands of years and don’t break down. They are associated with medical problems like cancer and other issues connected to fertility, thyroid, liver damage, reduced antibody response to vaccines, kidney and testicular cancer, and the immune system. The firefighting foam lawsuits were joined in multidistrict litigation (Aqueous Film-Forming Foams (AFFF) Products Liability Litigation (MDL No. 2873). Recently 3M agreed to settle personal injury claims related to the forever chemicals used in firefighting foam for $7.35 billion. If you have been harmed by forever chemicals, call the seasoned Chicago-based lawyers of Moll Law Group. Billions have been recovered in cases with which we’ve been involved.
Consult Moll Law Group About Your Claim
Forever chemicals are used not only in firefighting foam but also in products that are resistant to water, grease, stain, and heat. In reaching a settlement, 3M didn’t admit liability. The settlement payment structure involves a $50 million payment in 2026, no payments in 2027, and around 20% of payments owing in the final two years. 3M anticipates recording a pre-tax charge of $5.8 billion in the fourth quarter.
This most recent settlement is expected to cover 115,000-120,000 plaintiffs and address 99% of personal injury lawsuits. A 2023 settlement with many U.S. public water systems to resolve water pollution claims that were linked to forever chemicals was $10 billion. A settlement was also reached with the State of New Jersey.
Illinois Injury and Mass Tort Lawyer Blog





On October 1, Walmart recalled more than 4.4. million expert grill brushes of various types because it was found that the thin metal wire bristles could come off the brushes and stick to food or the grill, presenting the risk of consumption and hazard of serious internal injuries requiring surgery. Around
Apple was sued in Illinois federal court by
Nevro received FDA approval for the Senza spinal cord stimulator system (SCS) providing HF10 therapy in May 2015. This system was different from conventional stimulators because it was designed to provide electrical pulses at a much higher frequency directly to the spinal cord. The Nevro spinal cord stimulator (SCS) lawsuits claim that specific Senza, HF10, and HFX systems don’t offer the pain relief they promise and cause significant complications. These lawsuits allege there were inadequate warnings, manufacturing defects, misrepresentations, improper device programming, and post-market reporting failures. Plaintiffs claim that changes made through the FDA’s premarket approval supplements changed the components of the device with inadequate clinical validation and disclosure. Plaintiffs requested centralization of the lawsuits. In June, an industry-wide multidistrict litigation was denied, but on October 2,
Chronic pain is debilitating. Neurostimulation or spinal cord stimulation (SCS) is one type of pain management; it works by sending low intensity electrical impulses to a patient’s nerve structures. Abbott makes various kinds of SCS systems that plaintiffs allege are flawed and caused injuries. Lawsuits have been filed that allege the SCS implants can break through skin, migrate, give painful shocks, cause nerve damage and fail outright; these may require expensive revision or removal surgery. On October 2, the JPML centralized
Hamilton Medical, Inc. ventilator coaxial breathing circuits are used to connect HAMILTON-C1/T1/MR1 ventilators to a patient tube or respiratory mask in the course of ventilation of a patient. Recently, the Food and Drug Administration (FDA) announced that it is aware that the manufacturer Hamilton Medical has sent a
Pregabalin is a drug also known by the brand name Lyrica. It’s used to treat epilepsy and nerve pain. It is sometimes used off label to treat chronic back pain, anxiety, or insomnia. Several studies show that pregabalin use is linked to cognitive decline. A
Gabapentin is a prescription medication, gamma aminobutyric acid (GABA) analogue, that reduces the excitability of neurons. It is used to control and prevent partial seizures, to relieve neuralgia, and to treat restless legs syndrome. It’s also used off label to address anxiety disorders, migraines, insomnia, drug and alcohol withdrawal symptoms, and for non-approved pain problems like nerve pain from sciatica. The brand names of gabapentin are Neurontin, Horizant, and Gralise. Some states have classified gabapentin as a Schedule V controlled substance due to the number of deaths from overdose, but prescriptions are climbing anyway.
On August 3, 2026, plaintiffs filed
In June, the Consumer Product Safety Commission (CPSC) and Galanz Americas Limited announced a recall of the latter’s